Differences in Incidence of Acute Viral Hepatitis between Foreigners and Autochthonous Population in Italy.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
27 07 2021
Historique:
received: 15 06 2021
revised: 21 07 2021
accepted: 23 07 2021
entrez: 7 8 2021
pubmed: 8 8 2021
medline: 14 8 2021
Statut: epublish

Résumé

In European countries, the prevalence of HBV and HCV in refugees and migrants tends to reflect the prevalence in their countries of origin. The aim of this study is to analyse acute viral hepatitis cases diagnosed in Italy among foreign citizens and to compare incidence rates in foreigners and Italians. We analysed the cases of each viral hepatitis type among foreigners. Standardised incidence rates were compared between natives and foreigners. Between 2004 and 2019, 15,872 cases of acute viral hepatitis were notified by 10 Italian regions, 14.8% among foreign citizens. Until 2012, the percentage increased gradually, while a fluctuating trend set in from 2013 onwards; in 2019, 23.9% of cases were foreigners. Data from the SEIEVA surveillance show higher standardised incidence rates of hepatitis A and B among foreign citizens; no significant difference emerged between Italians and foreigners in terms of their hepatitis C incidence. foreign citizens have an increased incidence of hepatitis A and B. Regarding hepatitis A, vaccination is strongly recommended to foreigners travelling to their countries of origin. Screening tests for hepatitis B and C infection should be offered to newly arrived migrants from high prevalence countries, or having specific risk factors.

Sections du résumé

BACKGROUND
In European countries, the prevalence of HBV and HCV in refugees and migrants tends to reflect the prevalence in their countries of origin. The aim of this study is to analyse acute viral hepatitis cases diagnosed in Italy among foreign citizens and to compare incidence rates in foreigners and Italians.
METHODS
We analysed the cases of each viral hepatitis type among foreigners. Standardised incidence rates were compared between natives and foreigners.
RESULTS
Between 2004 and 2019, 15,872 cases of acute viral hepatitis were notified by 10 Italian regions, 14.8% among foreign citizens. Until 2012, the percentage increased gradually, while a fluctuating trend set in from 2013 onwards; in 2019, 23.9% of cases were foreigners. Data from the SEIEVA surveillance show higher standardised incidence rates of hepatitis A and B among foreign citizens; no significant difference emerged between Italians and foreigners in terms of their hepatitis C incidence.
CONCLUSIONS
foreign citizens have an increased incidence of hepatitis A and B. Regarding hepatitis A, vaccination is strongly recommended to foreigners travelling to their countries of origin. Screening tests for hepatitis B and C infection should be offered to newly arrived migrants from high prevalence countries, or having specific risk factors.

Identifiants

pubmed: 34360239
pii: ijerph18157944
doi: 10.3390/ijerph18157944
pmc: PMC8345609
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Dig Liver Dis. 2017 Dec;49(12):1368-1372
pubmed: 28818677
Epidemiol Prev. 2021 May-Jun;45(3):173-180
pubmed: 34212698
J Infect Public Health. 2019 Mar - Apr;12(2):200-204
pubmed: 30377049
Vaccine. 2013 Apr 3;31(14):1806-11
pubmed: 23395735
Infect Dis Poverty. 2019 Mar 15;8(1):17
pubmed: 30871599
Health Policy. 2021 Mar;125(3):393-405
pubmed: 33461797
Eur J Obstet Gynecol Reprod Biol. 2020 Nov;254:195-199
pubmed: 33017709
World J Clin Cases. 2018 Nov 6;6(13):589-599
pubmed: 30430114
Hum Vaccin Immunother. 2013 Mar;9(3):636-41
pubmed: 23354158
Infect Dis Poverty. 2017 Feb 9;6(1):33
pubmed: 28179020
Public Health. 2018 May;158:176-182
pubmed: 29628202
Epidemiol Prev. 2021 Jan-Apr;45(1-2):46-53
pubmed: 33884842
J Infect Public Health. 2017 Mar - Apr;10(2):177-184
pubmed: 27161593
Scand J Gastroenterol. 2017 Aug;52(8):893-897
pubmed: 28446048
Public Health. 2020 Aug;185:394-399
pubmed: 32758763
Public Health Rev. 2017 Sep 8;38:22
pubmed: 29450094
J Viral Hepat. 2020 Sep;27(9):941-947
pubmed: 32338810
PLoS Med. 2020 Apr 21;17(4):e1003068
pubmed: 32315297
J Travel Med. 2019 Feb 1;26(2):
pubmed: 30726941
Infez Med. 2016 Sep 1;24(3):210-6
pubmed: 27668901
Clin Infect Dis. 2016 Jun 1;62(11):1412-8
pubmed: 27009250
Public Health. 2015 May;129(5):561-8
pubmed: 25795017
Euro Surveill. 2018 Oct;23(41):
pubmed: 30326991
Eur J Intern Med. 2018 Jul;53:79-84
pubmed: 29475770
Int J Infect Dis. 2020 Dec;101:126-130
pubmed: 32947054
BMC Public Health. 2017 Apr 22;17(1):351
pubmed: 28431498
Lancet Infect Dis. 2018 Sep;18(9):e259-e271
pubmed: 29778396
Euro Surveill. 2018 Jul;23(27):
pubmed: 29991381
Euro Surveill. 2015 Jul 23;20(29):21192
pubmed: 26227370
Euro Surveill. 2018 Aug;23(33):
pubmed: 30131095
Euro Surveill. 2018 Feb;23(6):
pubmed: 29439751
East Mediterr Health J. 2019 Jun 04;25(4):246-253
pubmed: 31210345

Auteurs

Franca D'Angelo (F)

National Center for Global Health, National Institute of Health, 00161 Rome, Italy.

Luigina Ferrigno (L)

National Center for Global Health, National Institute of Health, 00161 Rome, Italy.

Annamaria Mele (A)

Department of Public Health and Infectious Diseases, University "La Sapienza", 00185 Rome, Italy.

Valeria Alfonsi (V)

Health Management, Sant'Andrea Hospital, 00189 Rome, Italy.

Silvia Declich (S)

National Center for Global Health, National Institute of Health, 00161 Rome, Italy.

Giulia De Ponte (G)

National Center for Global Health, National Institute of Health, 00161 Rome, Italy.

Simonetta Crateri (S)

National Center for Global Health, National Institute of Health, 00161 Rome, Italy.

Alessandra Burgio (A)

Health Unit, National Institute of Statistics (ISTAT), 00184 Rome, Italy.

Susanna Caminada (S)

Department of Public Health and Infectious Diseases, University "La Sapienza", 00185 Rome, Italy.

Maria Elena Tosti (ME)

National Center for Global Health, National Institute of Health, 00161 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH